Brief: Adicet Bio Q2 Basic EPS USD -0.33
13/08/2024 12:00
Aug 13 (Reuters) - Adicet Bio Q2 operating income USD -32.849 million vs. IBES estimate USD -31.1 million. * Q2 operating expenses USD 32.849 million * Q2 net income USD -29.901 million vs. IBES estimate USD -29.1 million
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary